Form 6K Opthea Ltd For: 12 November
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ceryvyn Therapeutics Ltd ADR (OPTEY)
The Ceryvyn ADR share price today is 0.022, view OTC OPTEY stock exchange data. Track the latest Ceryvyn ADR share price with real-time updates on OPTEY stock performance including market cap, day range, 52-week range and dividend yield. Access OPTEY charts, earnings dates and analyst estimates to support your investment decisions.
0.022
-0.001(-3.91%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.022
0.022
52 wk Range
0.002
3.170
OPTEY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0220.022
52 wk Range
0.0023.170
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
OPTEY Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
1.000
Upside
+4,445.45%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Optiva Inc. Announces Results of Annual Meeting
- Investing.com
- Form 6K Opthea Ltd For: 31 October
- Investing.com
- Form 6K Opthea Ltd For: 27 October
- Investing.com
- Form 6K Opthea Ltd For: 12 November
- Investing.com
- Form 6K Opthea Ltd For: 31 October
- Investing.com
- Form 6K Opthea Ltd For: 27 October
- Investing.com
- Form 6K Opthea Ltd For: 19 August
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 1.000
(+4,445.45% Upside)
Earnings
Latest Release
03-06-2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
Compare OPTEY to Peers and Sector
Metrics to compare | OPTEY | Peers Peers - average of corresponding metrics from companies closely matching OPTEY: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOPTEYPeersSector |
|---|---|---|---|---|
P/E Ratio | 0.1x | 0.0x | −0.4x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.5x | 0.0x | 2.6x | |
Price / LTM Sales | −884.0x | 0.0x | 3.0x | |
Upside (Analyst Target) | - | 0.0% | 51.9% | |
Fair Value Upside | Unlock | 0.0% | 9.4% | Unlock |
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company’s pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Ceryvyn ADR (OPTEY) Share Price Today?
The Ceryvyn ADR share price today is 0.022.
What is the current Ceryvyn ADR (OPTEY) share price and day range?
As of 09-07-2026, the Ceryvyn ADR share price is 0.022, with a previous close of 0.023. The share price has ranged from 0.022 to 0.022 today, while the 52-week range spans from 0.002 to 3.170.
What Is the Ceryvyn ADR Market Cap?
As of today, Ceryvyn ADR market cap is 9.490M.
What Is the Ceryvyn ADR (OPTEY) Share Price Target?
The average 12-month share price target for Ceryvyn ADR is 1.000, with a high estimate of 1 and a low estimate of 1. 0 analysts recommend buying, while 0 suggest selling, with an overall rating of Neutral and +4,445.45% Upside potential.
What Is Ceryvyn ADR's Earnings Per Share (TTM)?
The Ceryvyn ADR EPS (TTM) is 0.232.
When Is the Next Ceryvyn ADR Earnings Date?
Ceryvyn ADR will release its next earnings report on 28-08-2026.
From a Technical Analysis Perspective, Is OPTEY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Ceryvyn ADR Trade On?
Ceryvyn ADR is listed and trades on the OTC Markets.
What Is the Stock Symbol for Ceryvyn ADR?
The stock symbol for Ceryvyn ADR is "OPTEY."
How Many Times Has Ceryvyn ADR Stock Split?
Ceryvyn ADR has split 1 times.
How Many Employees Does Ceryvyn ADR Have?
Ceryvyn ADR has 33 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.